Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) is a biotechnology company developing T-cell immunotherapies, with its current business centered on tab-cel (tabelecleucel), an allogeneic, Epstein-Barr virus-specific T-cell therapy for EBV-positive post-transplant lymphoproliferative disease. Marketed as Ebvallo, tab-cel is… From the company’s description.
Over the twelve months to Jun 30, 2026, Atara Biotherapeutics, Inc. reported revenue of $6.19M, down 96.7% from a year earlier, and a net loss of $16.69M. Its operating margin was −229.7%, and operations used $21.89M in cash. In fiscal 2025, it reported revenue of $120.77M, down 6.3% from fiscal 2024, and net income of $32.69M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Atara Biotherapeutics, Inc. does
In the company’s own words
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) is a biotechnology company developing T-cell immunotherapies, with its current business centered on tab-cel (tabelecleucel), an allogeneic, Epstein-Barr virus-specific T-cell therapy for EBV-positive post-transplant lymphoproliferative disease. Marketed as Ebvallo, tab-cel is authorized for sale in the European Economic Area, the United Kingdom and Switzerland; Pierre Fabre holds worldwide rights and is responsible for its development, manufacturing, regulatory activities and commercialization. Tab-cel is also being developed for other EBV-driven diseases. Atara’s off-the-shelf platform uses prepared donor T cells selected to match a patient’s immune profile. The company previously developed allogeneic CAR T programs targeting CD19 and CD19/CD20, but paused and discontinued their operations in 2025; it also stopped developing its multiple-sclerosis program. Atara is reviewing strategic alternatives. It reported $[not stated] in revenue for fiscal 2025. Its website is www.atarabio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- THOUSAND OAKS, CA
- Fiscal year end
- December
- CIK
- 1604464
- SIC
- 2836
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Atara Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Atara Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Atara Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Atara Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Atara Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”